Stepan Co Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.4B+11.6% YoYTTM through 30 Jun 2026
Net Income -$2.7M-105.3% YoYTTM through 30 Jun 2026
Free Cash Flow $36.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 11.6% |
| EBITDA Margin | 6.1% |
| Operating Margin | 3.4% |
| Net Margin | -0.1% |
Returns
-0.2%ROE
-0.1%ROA
-0.2%ROIC
Balance Sheet Health
Debt / Equity0.50x
Current Ratio1.29x
Net Debt$494M
Cash & Equivalents$113.7M
Quality Metrics
Altman Z-Score2.58
Piotroski F-Score5 / 9
FCF Margin1.5%
Rule of 405.6
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $2.3B
Diluted EPS-$0.12TTMFY2025: $2.05
Dividend
$0.79Per share, FY20261.23%Yield-8.8%5-yr growth
Capital Allocation
R&D Spend$34.8M
Capex Intensity4.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Surfactants | $1.7B | ||
| Polymers | $583M | ||
| Specialty Products | $93.3M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.